Associated Genetic Biomarkers
NCI Definition: A WHO grade II tumor composed of a conspicuous mixture of two distinct neoplastic cell types morphologically resembling the tumor cells in oligodendroglioma and diffuse astrocytoma. (WHO) 
Oligoastrocytomas most frequently harbor alterations in IDH1, TP53, and ATRX .
IDH1 Mutation, IDH1 Codon 132 Missense, IDH1 R132H, TP53 Mutation, and TP53 c.217-c.1178 Missense are the most common alterations in oligoastrocytoma .
There are 2 clinical trials for oligoastrocytoma, of which 2 are open and 0 are completed or closed. Of the trials that contain oligoastrocytoma as an inclusion criterion, 1 is phase 1 (1 open) and 1 is phase 2 (1 open).
IDH1 and IDH2 are the most frequent gene inclusion criteria for oligoastrocytoma clinical trials .
Ima950, poly iclc, and proton beam radiation therapy are the most common interventions in oligoastrocytoma clinical trials.
Significant Genes in Oligoastrocytoma
IDH2 is an inclusion eligibility criterion in 1 clinical trial for oligoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and oligoastrocytoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.